{"organizations": [], "uuid": "ae758b1904b4765f181dfb81365c70f188d5f9d1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-q-state-biosciences-says-entered-s/brief-q-state-biosciences-says-entered-strategic-collaboration-with-vertex-pharmaceuticals-idUSFWN1RH0EY", "country": "US", "domain_rank": 408, "title": "BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-04T15:11:00.000+03:00", "replies_count": 0, "uuid": "ae758b1904b4765f181dfb81365c70f188d5f9d1"}, "author": "", "url": "https://www.reuters.com/article/brief-q-state-biosciences-says-entered-s/brief-q-state-biosciences-says-entered-strategic-collaboration-with-vertex-pharmaceuticals-idUSFWN1RH0EY", "ord_in_thread": 0, "title": "BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "vertex pharmaceuticals", "sentiment": "negative"}, {"name": "vertex pharmaceuticals inc", "sentiment": "none"}, {"name": "vertex", "sentiment": "none"}, {"name": "vertex pharmaceuticals reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 4, 2018 / 12:12 PM / in 12 minutes BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals Reuters Staff \nApril 4 (Reuters) - Vertex Pharmaceuticals Inc: * COâ€™S NOVEL OPTOPATCH PLATFORM \n* PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES * STATE WILL ALSO RECEIVE ROYALTIES ON DRUG SALES \n* CO, VERTEX PHARMACEUTICALS WILL COLLABORATE FOR AT LEAST TWO YEARS \n* VERTEX IS RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-04-04T15:11:00.000+03:00", "crawled": "2018-04-04T15:39:43.006+03:00", "highlightTitle": ""}